You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
IEM 1925 dihydrobromide
Biological Activity for IEM 1925 dihydrobromide
IEM 1925 dihydrobromide is a voltage- and use-dependent open-channel antagonist of AMPA receptors. Selective between subtypes; blocks GluA2 subunit-lacking receptors more potently than GluA2-containing receptors (KD for GluA2-containing AMPAR is 210 times higher at -80 mV). More potent than IEM 1460 (Cat. No. 1636) and IEM 1754 (Cat. No. 4199) due to a slower unblocking rate. Alleviates inflammatory pain in a rat model of peripheral inflammation.
Compound Libraries for IEM 1925 dihydrobromide
Technical Data for IEM 1925 dihydrobromide
|Storage||Desiccate at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for IEM 1925 dihydrobromide
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for IEM 1925 dihydrobromide
The following data is based on the product molecular weight 422.24. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.37 mL||11.84 mL||23.68 mL|
|5 mM||0.47 mL||2.37 mL||4.74 mL|
|10 mM||0.24 mL||1.18 mL||2.37 mL|
|50 mM||0.05 mL||0.24 mL||0.47 mL|
Product Datasheets for IEM 1925 dihydrobromide
References for IEM 1925 dihydrobromide
References are publications that support the biological activity of the product.
Tikhonov et al (2000) Voltage-dependent block of native AMPA receptor channels by dicationic compounds. Br.J.Pharmacol. 129 265 PMID: 10694232
Kopach et al (2016) Inhibition of spinal Ca2+-permeable AMPA receptors with dicationic compounds alleviates persistent inflammatory pain without adverse effects. Front.Cell Neurosci. 10 PMID: 26973464
If you know of a relevant reference for IEM 1925 dihydrobromide, please let us know.
View Related Products by Product Action
Keywords: IEM 1925 dihydrobromide, IEM 1925 dihydrobromide supplier, IEM1925, 2HBr, AMPAR, antagonist, blocks, AMPA, receptor, voltage-dependent, channel, blocker, Receptors, 4198, Tocris Bioscience
Citations for IEM 1925 dihydrobromide
Citations are publications that use Tocris products.
Currently there are no citations for IEM 1925 dihydrobromide. Do you know of a great paper that uses IEM 1925 dihydrobromide from Tocris? Please let us know.
Reviews for IEM 1925 dihydrobromide
There are currently no reviews for this product. Be the first to review IEM 1925 dihydrobromide and earn rewards!
Have you used IEM 1925 dihydrobromide?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.